ProPhase Labs Inc (NASDAQ:PRPH) CEO Ted William Karkus sold 424,789 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $2.30, for a total value of $977,014.70. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ted William Karkus also recently made the following trade(s):

  • On Friday, September 29th, Ted William Karkus sold 364,950 shares of ProPhase Labs stock. The stock was sold at an average price of $2.30, for a total value of $839,385.00.

Shares of ProPhase Labs Inc (NASDAQ PRPH) traded down $0.01 during trading hours on Tuesday, hitting $2.19. The stock had a trading volume of 1,700 shares, compared to its average volume of 21,230. The stock has a market cap of $27.22, a price-to-earnings ratio of 0.96 and a beta of 0.18. ProPhase Labs Inc has a fifty-two week low of $1.78 and a fifty-two week high of $2.45.

ProPhase Labs (NASDAQ:PRPH) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.05) EPS for the quarter. The firm had revenue of $3.04 million for the quarter. ProPhase Labs had a return on equity of 40.36% and a net margin of 307.58%.

ProPhase Labs declared that its Board of Directors has initiated a stock buyback program on Friday, November 10th that authorizes the company to buyback 1,700,000 shares. This buyback authorization authorizes the company to purchase shares of its stock through a tender offer. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Separately, ValuEngine lowered ProPhase Labs from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th.

TRADEMARK VIOLATION NOTICE: “ProPhase Labs Inc (PRPH) CEO Ted William Karkus Sells 424,789 Shares” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at

About ProPhase Labs

ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with's FREE daily email newsletter.